ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0174

Dense Genotyping of Immunologic Loci Identifies CXCR4 as a Novel Susceptibility Locus for Systemic Juvenile Idiopathic Arthritis
Abstract Number: 0175

Identifying Immuno-phenotypes in Juvenile Localized Scleroderma with RNA Sequencing
Abstract Number: 0176

Characterization and Molecular Mechanism Underlying NEMO Deleted Exon 5 Autoinflammatory Syndrome (NDAS)
Abstract Number: 0177

Association of Hydroxychloroquine Use with Development of Non-Alcoholic Fatty Liver Disease in Rheumatoid Arthritis
Abstract Number: 0178

Associations of Multimorbidity with DMARD Initiation and Achieving Target Disease Activity Thresholds in Active Rheumatoid Arthritis: A Cohort Study Using the Rheumatology Informatics System for Effectiveness (RISE) Registry
Abstract Number: 0179

Identification of Multimorbidity Patterns in Rheumatoid Arthritis Through Machine Learning
Abstract Number: 0180

Clinicopathological Characteristics of Lymphoproliferative Disorders in 232 Patients with Rheumatoid Arthritis in Japan
Abstract Number: 0181

Methotrexate Use Does Not Increase the Prevalence of Hepatic Steatosis: A Real-World Retrospective Nested Case-Control Study
Abstract Number: 0182

Chronic Kidney Disease Is Underestimated in Patients with Rheumatoid Arthritis – Real World Data Gathered from a Network of Rheumatologists
Abstract Number: 0183

Incidence of Malignancies in Japanese Patients with Rheumatoid Arthritis: Data from a Large Japanese National Registry
Abstract Number: 0184

Lymphomas Complicating Rheumatoid Arthritis: Results of a French Multi-Centre Case-Control Study
Abstract Number: 0185

Prevalence of Migraine and Neuropathic Pain in Rheumatic Disease
Abstract Number: 0186

The Number of Associated Comorbidities Can Impact Disease Activity Scores Independently from Objective Measures of Inflammation in Patients with Rheumatoid Arthritis
Abstract Number: 0187

Regional and Widespread Patterns of Non-articular Pain Are Common at RA Diagnosis and Contribute to Poor Outcomes at 12 Months: A Prospective Study of Pain Patterns in Canadians with RA
Abstract Number: 0188

The Risk of Fractures in a Community-based Cohort of Patients with Rheumatoid Arthritis Compared with the Background Population

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].